Chemical Properties:
Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureLeading manufacturer and supplier of Erlotinib Hydrochloride Intermediates Erlotinib Hydrochloride CAS 183319-69-9 3-Ethynylaniline CAS 54060-30-9 6,7-Bis(2-Methoxyethoxy)-3H-Quinazolin-4-one CAS 179688-29-0 Please contact: alvin@ruifuchem.com| Item | Specifications |
| Appearance | Light Yellow to Brown Liquid |
| Purity / Analysis Method | >99.0% (GC) |
| Water by Karl Fischer | <0.50% |
| Residue on Ignition | <0.20% |
| Total Impurities | <1.00% |
| Specific Gravity (20/20℃) | 1.041~1.048 |
| Refractive Index n20/D | 1.614~1.6195 |
| Infrared Spectrum | Conforms to Structure |
| Proton NMR Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Pharmaceutical Intermediate; Erlotinib Hydrochloride Intermediate |
Description:
Specifications:
Package & Storage:
| Chemical Name | 3-Ethynylaniline |
| Synonyms | 3-Aminophenylacetylene |
| CAS Number | 54060-30-9 |
| CAT Number | RF-PI2241 |
| Stock Status | In Stock, Production Capacity 50MT/Month |
| Molecular Formula | C8H7N |
| Molecular Weight | 117.15 |
| Sensitive | Air Sensitive, Light Sensitive |
| Boiling Point | 120℃/20 mmHg |
| Water Solubility | Insoluble in Water |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
3-Ethynylaniline, also known as 3-Aminophenylacetylene (CAS: 54060-30-9) is used as a pharmaceutical intermediate. 3-Ethynylaniline is an intermediate of Erlotinib Hydrochloride (CAS: 183319-69-9). Erlotinib Hydrochloride is a small molecule tyrosine kinase inhibitor which acts reversibly on epidermal growth receptors, a hydrochloride of erlotinib, a molecular-targeted drug. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as a first-line treatment for locally advanced and metastatic pancreatic cancer. It is mainly used as a second- or third-line treatment for locally advanced or metstatic non-small cell lung cancer (NSCLC) and as a treatment for pancreatic cancer. It is used as a tyrosine inhibitor for NSCLC treatment. Erlotinib Hydrochloride, a quinazoline derived small molecule inhibitor of epidermal growth receptor (EDGFR) tyrosine kinase, was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer.
